Find Netupitant manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

120RELATED EXCIPIENT COMPANIES

169EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Annual Reports

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 290297-26-6, 2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide, 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide, Ro-67-3189, Ro-673189000, Ro 67-3189/000
Molecular Formula
C30H32F6N4O
Molecular Weight
578.6  g/mol
InChI Key
WAXQNWCZJDTGBU-UHFFFAOYSA-N
FDA UNII
7732P08TIR

Netupitant
Netupitant is a selective neurokinin 1 (NK1) receptor antagonist with potential antiemetic activity. Netupitant competitively binds to and blocks the activity of the human substance P/NK1 receptors in the central nervous system (CNS), thereby inhibiting NK1-receptor binding of the endogenous tachykinin neuropeptide substance P (SP), which may result in the prevention of chemotherapy-induced nausea and vomiting (CINV). SP is found in neurons of vagal afferent fibers innervating the brain-stem nucleus tractus solitarii and the area postrema, which contains the chemoreceptor trigger zone (CTZ), and may be elevated in response to chemotherapy. The NK-receptor is a G-protein receptor coupled to the inositol phosphate signal-transduction pathway and is found in both the nucleus tractus solitarii and the area postrema.
Netupitant is a Substance P/Neurokinin-1 Receptor Antagonist. The mechanism of action of netupitant is as a Neurokinin 1 Antagonist, and Cytochrome P450 3A4 Inhibitor, and P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor.
1 2D Structure

Netupitant

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide
2.1.2 InChI
InChI=1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3
2.1.3 InChI Key
WAXQNWCZJDTGBU-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C
2.2 Other Identifiers
2.2.1 UNII
7732P08TIR
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl)propanamide

2. 2-(3,5-bis(trifluoromethyl)phenyl)-n-methyl-n-(4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl)-2-methylpropanamide

3. Benzeneacetamide, N, Alpha, Alpha-trimethyl-n-(4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl)-3,5-bis(trifluoromethyl)-

4. Benzeneacetamide, N, Alpha,alpha-trimethyl-n-(4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl)-3,5-bis(trifluoromethyl)-, Hydrochloride (1:2)

5. Netupitant Dihydrochloride

6. Netupitant Hydrochloride

7. Ro 67-3189 000

8. Ro 673189000

9. Ro-67-3189

10. Ro-67-3189 000

11. Ro-673189000

2.3.2 Depositor-Supplied Synonyms

1. 290297-26-6

2. 2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide

3. 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide

4. Ro-67-3189

5. Ro-673189000

6. Ro 67-3189/000

7. Chembl206253

8. Chebi:85155

9. 7732p08tir

10. Cid 6451149

11. Ro 67-31898/000

12. Benzeneacetamide, N,alpha,alpha-trimethyl-n-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-

13. 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl)propanamide

14. 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(6-(4-methylpiperazin-1-yl)-4-o-tolylpyridin-3-yl)propanamide

15. 2-[3,5-bis(trifluoromethyl)phenyl]-~{n},2-dimethyl-~{n}-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide

16. Netupitant [usan]

17. Netupitant [usan:inn]

18. Unii-7732p08tir

19. Benzeneacetamide, N,alpha,alpha-trimethyl-n-(4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl)-3,5-bis(trifluoromethyl)-

20. Cid6451149

21. Netupitant [mi]

22. Netupitant [inn]

23. Netupitant (usan/inn)

24. Netupitant [vandf]

25. Netupitant [who-dd]

26. Schembl445804

27. Gtpl5742

28. Netupitant(cid-6451149)

29. Netupitant [orange Book]

30. Dtxsid50183271

31. Glxc-15009

32. Hms3887e19

33. Bcp08751

34. Ex-a2747

35. Bdbm50178574

36. Mfcd25976831

37. S4654

38. Zinc11681563

39. Akos027251056

40. Ccg-270121

41. Cs-3337

42. Db09048

43. Sb18973

44. Cid-6451149

45. Ncgc00390569-01

46. 2-(3,5-bis(trifluoromethyl)phenyl)-n-methyl-n-(4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl)-2-methylpropanamide

47. Ac-29232

48. As-10239

49. Hy-16346

50. Ro 67-31898

51. Akynzeo Capsule Component Netupitant

52. Netupitant Component Akynzeo Capsule

53. Ft-0699740

54. A14428

55. D05152

56. Ro-67-3189/000

57. Q19598139

58. 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(6-(4-methylpiperazin-1-yl)-4-o-tolylpyridin-3-yl)propanamide, Aldrichcpr

59. 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(6-(4-methylpiperazin-1yl)-4-(o-tolyl)pyridin-3yl)propanamide

60. 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-[6-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-isobutyramide

61. 2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide

62. Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-n-(4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl)-3,5-bis(trifluoromethyl)-

63. Gaw

64. N,alpha,alpha-trimethyl-n-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-benzeneacetamide

2.4 Create Date
2006-04-29
3 Chemical and Physical Properties
Molecular Weight 578.6 g/mol
Molecular Formula C30H32F6N4O
XLogP36.8
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count10
Rotatable Bond Count5
Exact Mass578.24803063 g/mol
Monoisotopic Mass578.24803063 g/mol
Topological Polar Surface Area39.7 Ų
Heavy Atom Count41
Formal Charge0
Complexity865
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy.


FDA Label


5 Pharmacology and Biochemistry
5.1 FDA Pharmacological Classification
5.1.1 Active Moiety
NETUPITANT
5.1.2 FDA UNII
7732P08TIR
5.1.3 Pharmacological Classes
Mechanisms of Action [MoA] - Breast Cancer Resistance Protein Inhibitors
5.2 Absorption, Distribution and Excretion

Absorption

Upon oral administration of a single dose of netupitant, netupitant started to be measurable in plasma between 15 minutes and 3 hours after dosing. Plasma concentrations reached Cmax in approximately 5 hours. There was a greater than dose-proportional increase in the systemic exposure with the dose increase from 10 mg to 300 mg and a dose-proportional increase in systemic exposure with a dose increase from 300 mg to 450 mg.


Route of Elimination

Primarily fecal.


Volume of Distribution

In cancer patients, Vz/F: 1982 906 L (mean SD).


Clearance

Estimated systemic clearance of 20.3 9.2 L/h (mean SD).


5.3 Metabolism/Metabolites

Once absorbed, netupitant is extensively metabolized to form three major metabolites: desmethyl derivative, M1; N-oxide derivative, M2; and OH-methyl derivative, M3. Metabolism is mediated primarily by CYP3A4 and to a lesser extent by CYP2C9 and CYP2D6. Metabolites M1, M2 and M3 were shown to bind to the substance P/neurokinin 1 (NK1) receptor.


5.4 Biological Half-Life

96 hours with CV% of 61.


5.5 Mechanism of Action

Delayed emesis (vomiting) has been largely associated with the activation of tachykinin family neurokinin 1 (NK1) receptors (broadly distributed in the central and peripheral nervous systems) by substance P. As shown in in vitro and in vivo studies, netupitant inhibits substance P mediated responses.


API SUPPLIERS

read-more
read-more

01

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Metrochem

02

Viatris

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

Viatris

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Iran Expo
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

03

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Iran Expo
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT
blank

04

Helsinn Advanced Synthesis

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

Helsinn Advanced Synthesis

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Iran Expo
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

Apicore

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

Apicore

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Iran Expo
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

06

HAS Healthcare Advanced Synthesis

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

HAS Healthcare Advanced Synthesis

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Iran Expo
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

07

Guangzhou Tosun Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

08

Zhejiang Tiantai Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

09

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Iran Expo
Not Confirmed
USDMF CEP/COS JDMF EU-WCInactive-api NDC KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Netupitant

About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

02

Apicore

India
Iran Expo
Not Confirmed
arrow

Apicore

India
arrow
Iran Expo
Not Confirmed

Netupitant

About the Company : Apicore LLC, a wholly owned subsidiary of RK Pharma Inc is a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry. We offer a wide p...

Apicore LLC, a wholly owned subsidiary of RK Pharma Inc is a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry. We offer a wide portfolio of services ranging from API’s for the generic industry to custom synthesis for early phase pharmaceutical research and branded products. Our USFDA approved facilities in India (Visakhapatnam, Andhra Pradesh and Vadodara, Gujarat) are both equipped with state-of-the-art analytical and research capabilities. While our worldwide network of locations seamlessly integrate with each other, each unit also independently houses a full
blank

03

Iran Expo
Not Confirmed
arrow
arrow
Iran Expo
Not Confirmed

Netupitant

About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...

Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Excipients, Herbal extracts, Formulation of Chinese & Western Medicine. With abundant economic strength, the group has successfully developed to a pharmaceutical group enterprise wich intergrets operation of medicine & related products, processing & manufacturing, and importation & exportation together.
blank

04

Viatris

U.S.A
Iran Expo
Not Confirmed
arrow

Viatris

U.S.A
arrow
Iran Expo
Not Confirmed

Netupitant

About the Company : In November 2020, Viatris was formed through the combination of Mylan and Upjohn, with a mission of empowering people worldwide to live healthier at every stage of life. Viatris (N...

In November 2020, Viatris was formed through the combination of Mylan and Upjohn, with a mission of empowering people worldwide to live healthier at every stage of life. Viatris (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020.
blank

05

Iran Expo
Not Confirmed
arrow
arrow
Iran Expo
Not Confirmed

Netupitant

About the Company : Zhejiang Tiantai Pharmaceutical Co., Ltd. (a company to be listed), established in June 1998, specializes in the research and development of clindamycin hydrochloride, clindamycin ...

Zhejiang Tiantai Pharmaceutical Co., Ltd. (a company to be listed), established in June 1998, specializes in the research and development of clindamycin hydrochloride, clindamycin phosphate, and amphotericin B and other antibiotics and antifungal series of characteristic raw materials, It is one of the main manufacturers of clindamycin hydrochloride and clindamycin phosphate both at home and abroad. The company focuses on the big health industry, and builds traditional specialty APIs, API CDMO & CRO business segments, and synthetic biology drug segments.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1657045800,"product":"NETUPITANT","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"ATHENS","customer":"TO THE ORDER OF","customerCountry":"GREECE","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"35000","totalValueFC":"6728.2","currency":"USD","unitRateINR":2675000,"date":"06-Jul-2022","totalValueINR":"535000","totalValueInUsd":"6728.2","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"2643015","productDescription":"API","marketType":"REGULATED MARKET","country":"GREECE","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1693333800,"product":"NETUPITANT","address":"MSN HOUSE PLOT NO. C-24INDUSTRI AL ESTATE SANATH NAGAR","city":"Hyderabad","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"NA","customer":"TO THE ORDER OF","customerCountry":"UNITED STATES","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"48783.5","totalValueFC":"4840.9","currency":"USD","unitRateINR":4010000.4119999995,"date":"30-Aug-2023","totalValueINR":"401000.0412","totalValueInUsd":"4840.9","indian_port":"HYDERABAD ICD","hs_no":"29335990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES OF AMERICA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD ICD","supplierAddress":"MSN HOUSE PLOT NO. C-24INDUSTRI AL ESTATE SANATH NAGAR, Hyderabad","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1637173800,"product":"AKYNZEO (FOSNETUPITANT AND PALONOSETRON, 235MG\/0.25MG CONCENTRATE FOR SOLUTION FOR INFUSION) 08-PNET) (1 BOTTLE) (08-PNE","address":"B\/2 MAHALAXMI CHAMBERS 22 BHULABHAI DESAI ROAD Contact No:","city":"MUMBAI","supplier":"HELSINN ADVANCED SYNTHESIS","supplierCountry":"SWITZERLAND","foreign_port":"NA","customer":"GLENMARK PHARMACEUTICALS","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.00014","unit":"KGS","unitRateFc":"355000","totalValueFC":"55.7","currency":"CHF","unitRateINR":"29607000","date":"18-Nov-2021","totalValueINR":"4144.98","totalValueInUsd":"55.7","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"6310398","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"B\/2 MAHALAXMI CHAMBERS 22 BHULABHAI DESAI ROAD Contact No:"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1637173800,"product":"AKYNZEO (FOSNETUPITANT AND PALONOSETRON, 235MG\/0.25MG CONCENTRATE FOR SOLUTION FOR INFUSION) 14-NETU) (1 BOTTLE) (14-NET","address":"B\/2 MAHALAXMI CHAMBERS 22 BHULABHAI DESAI ROAD Contact No:","city":"MUMBAI","supplier":"HELSINN ADVANCED SYNTHESIS","supplierCountry":"SWITZERLAND","foreign_port":"NA","customer":"GLENMARK PHARMACEUTICALS","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.00015","unit":"KGS","unitRateFc":"105000","totalValueFC":"17.6","currency":"CHF","unitRateINR":"8757000","date":"18-Nov-2021","totalValueINR":"1313.55","totalValueInUsd":"17.6","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"6310398","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"B\/2 MAHALAXMI CHAMBERS 22 BHULABHAI DESAI ROAD Contact No:"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1637173800,"product":"AKYNZEO (FOSNETUPITANT AND PALONOSETRON, 235MG\/0.25MG CONCENTRATE FOR SOLUTION FOR INFUSION) 08-PALO) (1 BOTTLE) (08-PAL","address":"B\/2 MAHALAXMI CHAMBERS 22 BHULABHAI DESAI ROAD Contact No:","city":"MUMBAI","supplier":"HELSINN ADVANCED SYNTHESIS","supplierCountry":"SWITZERLAND","foreign_port":"NA","customer":"GLENMARK PHARMACEUTICALS","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.00021","unit":"KGS","unitRateFc":"650000","totalValueFC":"152.9","currency":"CHF","unitRateINR":"54210000","date":"18-Nov-2021","totalValueINR":"11384.1","totalValueInUsd":"152.9","indian_port":"BOMBAY AIR","hs_no":"29337990","bill_no":"6310398","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"B\/2 MAHALAXMI CHAMBERS 22 BHULABHAI DESAI ROAD Contact No:"}]
18-Nov-2021
30-Aug-2023
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Lubricants & Glidants

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Coating Systems & Additives

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Direct Compression

read-more
read-more

Empty Capsules

read-more
read-more

Co-Processed Excipients

read-more
read-more

Granulation

read-more
read-more

Taste Masking

read-more
read-more

Parenteral

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Controlled & Modified Release

read-more
read-more

Emulsifying Agents

read-more
read-more

Solubilizers

read-more
read-more

Coloring Agents

read-more
read-more

Topical

read-more
read-more

Rheology Modifiers

read-more
read-more

API Stability Enhancers

read-more
read-more

Soft Gelatin

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 290297-26-6 / Netupitant API manufacturers, exporters & distributors?

Netupitant manufacturers, exporters & distributors 1

57

PharmaCompass offers a list of Netupitant API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Netupitant manufacturer or Netupitant supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Netupitant manufacturer or Netupitant supplier.

PharmaCompass also assists you with knowing the Netupitant API Price utilized in the formulation of products. Netupitant API Price is not always fixed or binding as the Netupitant Price is obtained through a variety of data sources. The Netupitant Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Netupitant

Synonyms

290297-26-6, 2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide, 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide, Ro-67-3189, Ro-673189000, Ro 67-3189/000

Cas Number

290297-26-6

Unique Ingredient Identifier (UNII)

7732P08TIR

About Netupitant

Netupitant is a selective neurokinin 1 (NK1) receptor antagonist with potential antiemetic activity. Netupitant competitively binds to and blocks the activity of the human substance P/NK1 receptors in the central nervous system (CNS), thereby inhibiting NK1-receptor binding of the endogenous tachykinin neuropeptide substance P (SP), which may result in the prevention of chemotherapy-induced nausea and vomiting (CINV). SP is found in neurons of vagal afferent fibers innervating the brain-stem nucleus tractus solitarii and the area postrema, which contains the chemoreceptor trigger zone (CTZ), and may be elevated in response to chemotherapy. The NK-receptor is a G-protein receptor coupled to the inositol phosphate signal-transduction pathway and is found in both the nucleus tractus solitarii and the area postrema.

AKYNZEO Manufacturers

A AKYNZEO manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of AKYNZEO, including repackagers and relabelers. The FDA regulates AKYNZEO manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. AKYNZEO API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of AKYNZEO manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

AKYNZEO Suppliers

A AKYNZEO supplier is an individual or a company that provides AKYNZEO active pharmaceutical ingredient (API) or AKYNZEO finished formulations upon request. The AKYNZEO suppliers may include AKYNZEO API manufacturers, exporters, distributors and traders.

click here to find a list of AKYNZEO suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

AKYNZEO USDMF

A AKYNZEO DMF (Drug Master File) is a document detailing the whole manufacturing process of AKYNZEO active pharmaceutical ingredient (API) in detail. Different forms of AKYNZEO DMFs exist exist since differing nations have different regulations, such as AKYNZEO USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A AKYNZEO DMF submitted to regulatory agencies in the US is known as a USDMF. AKYNZEO USDMF includes data on AKYNZEO's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The AKYNZEO USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of AKYNZEO suppliers with USDMF on PharmaCompass.

AKYNZEO KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a AKYNZEO Drug Master File in Korea (AKYNZEO KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of AKYNZEO. The MFDS reviews the AKYNZEO KDMF as part of the drug registration process and uses the information provided in the AKYNZEO KDMF to evaluate the safety and efficacy of the drug.

After submitting a AKYNZEO KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their AKYNZEO API can apply through the Korea Drug Master File (KDMF).

click here to find a list of AKYNZEO suppliers with KDMF on PharmaCompass.

AKYNZEO WC

A AKYNZEO written confirmation (AKYNZEO WC) is an official document issued by a regulatory agency to a AKYNZEO manufacturer, verifying that the manufacturing facility of a AKYNZEO active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting AKYNZEO APIs or AKYNZEO finished pharmaceutical products to another nation, regulatory agencies frequently require a AKYNZEO WC (written confirmation) as part of the regulatory process.

click here to find a list of AKYNZEO suppliers with Written Confirmation (WC) on PharmaCompass.

AKYNZEO NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing AKYNZEO as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for AKYNZEO API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture AKYNZEO as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain AKYNZEO and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a AKYNZEO NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of AKYNZEO suppliers with NDC on PharmaCompass.

AKYNZEO GMP

AKYNZEO Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of AKYNZEO GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right AKYNZEO GMP manufacturer or AKYNZEO GMP API supplier for your needs.

AKYNZEO CoA

A AKYNZEO CoA (Certificate of Analysis) is a formal document that attests to AKYNZEO's compliance with AKYNZEO specifications and serves as a tool for batch-level quality control.

AKYNZEO CoA mostly includes findings from lab analyses of a specific batch. For each AKYNZEO CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

AKYNZEO may be tested according to a variety of international standards, such as European Pharmacopoeia (AKYNZEO EP), AKYNZEO JP (Japanese Pharmacopeia) and the US Pharmacopoeia (AKYNZEO USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty